Answers are grounded in this paper and cite their sources.
The efficacy and safety profile from this study supports extended omalizumab treatment up to 1 year for CRSwNP with inadequate response to nasal corticosteroids.
No takes yet. Share an insight, caveat, or question.
Gevaert et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: